Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy

Journal of Laboratory Automation

Volumn 21, Issue 1, 2016, Pages 178-187

  Blom, Kristin ^a   Nygren, Peter ^a   Alvarsson, Jonathan ^a   Larsson, Rolf ^a   Andersson, Claes R ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

chemotherapy; ex vivo; tailored cancer therapy; tumor cell

Indexed keywords

CELLS; CHEMOTHERAPY; COMPUTER AIDED DIAGNOSIS; CYTOLOGY; DIAGNOSIS; DISEASES; ONCOLOGY; TUMORS;

AUTOMATIC GENERATION; CANCER THERAPY; DRUG ACTIVITIES; EMPIRICAL MODEL; EX-VIVO; INTEGRATED SYSTEMS; STANDARD PROTOCOLS; TUMOR CELLS;

PATIENT TREATMENT;

ACOUSTIC DRUG DISPENSING; ACOUSTIC TECHNOLOGY; ARTICLE; CANCER THERAPY; CELL COUNT; CELL SURVIVAL; CELL VIABILITY ASSAY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG ACTIVITY; DRUG RESPONSE; FLUOROMETRY; HEMODYNAMICS; HUMAN; HUMAN CELL; TUMOR CELL; ACOUSTICS; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; DRUG SCREENING; NEOPLASM; PROCEDURES;

ANTINEOPLASTIC AGENT;

ACOUSTICS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CELLS, CULTURED; CYTOLOGICAL TECHNIQUES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS;

EID: 84955447828     PISSN: 22110682     EISSN: 22110690     Source Type: Journal    
DOI: 10.1177/2211068215598117     Document Type: Article

References (15)

1. P.NygrenR.LarssonPredictive Tests for Individualization of Pharmacological Cancer Treatment. Exp. Opin. Med. Diagn. 2008, 3, 349–360.
2. P.NygrenH.FridborgK.Csoka. Detection of Tumor Specific Cytotoxic Drug Activity In Vitro Using the Fluorometric Microculture Cytotoxicity Assay and Primary Cultures of Tumor Cells from Patients. Int. J. Cancer. 1994, 56, 715–720.
3. L.WeisenthalM.LippmanClonogenic and Nonclonogenic In Vitro Chemosensitivity Assays. Cancer Treat. Rep. 1985, 69, 615–632.
4. A.G.BosanquetP.NygrenL.M.WeisenthalIndividualized Tumor Response Testing in Leukemia and Lymphoma. In Innovative Leukemia and Lymphoma Therapy;, Eds.; Informa Healthcare, London, 2008, pp 440.
5. R.LarssonJ.KristensenC.Sandberg. Laboratory Determination of Chemotherapeutic Drug Resistance in Tumor Cells from Patients with Leukemia Using a Fluorometric Microculture Cytotoxicity Assay (FMCA). Int. J. Cancer1992, 50, 177–185.
6. K.CsokaB.TholanderE.Gerdin. In Vitro Determination of Cytotoxic Drug-Response in Ovarian Carcinoma Using the Fluorometric Microculture Cytotoxicity Assay (FMCA). Int. J. Cancer1997, 72, 1008–1012.
7. K.CsokaR.LarssonB.Tholander. Cytotoxic Drug Sensitivity Testing of Tumor Cells from Patients with Ovarian Carcinoma Using the Fluorometric Microculture Cytotoxicity Assay (FMCA). Gynecol. Oncol. 1994, 54, 163–170.
8. A.G.BosanquetCorrelations between Therapeutic Response of Leukaemias and In-Vitro Drug-Sensitivity Assay. Lancet1991, 337, 711–714.
9. R.LarssonH.FridborgJ.Kristensen. In Vitro Testing of Chemotherapeutic Drug Combinations in Acute Myelocytic Leukaemia Using the Fluorometric Microculture Cytotoxicity Assay (FMCA). Br. J. Cancer1997, 72, 1008–1012.
10. J.AlvarssonC.AnderssonO.Spjuth. An Open Source Laboratory Information System for Microplates with a Graphical Plate Layout Design Process. BMC Bioinform. 2011, 12: 179.
11. R.LarssonP.NygrenLaboratory Prediction of Clinical Chemotherapeutic Drug Resistance: A Working Model Exemplified by Acute Leukaemia. Eur. J. Cancer1993, 29, 1208–1212.
12. M.SandströmA.FreijsR.Larsson. Lack of Relationship between Systemic Exposure to the Component Drugs of the Fluorouracil, Epirubicin and 4-Hydroxycyclophosphamide Regimen in Breast Cancer Patients. J. Clin. Oncol. 1996, 14, 1581–1588.
13. A.S.CrystalA.T.ShawL.V.Sequist. Patient-Derived Models of Acquired Resistance Can Identify Effective Drug Combinations for Cancer. Science2014, 346, 1480–1486.
14. T.A.BennetP.MontesinosF.Moscardo. Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine. Clin. Lymphoma Myeloma Leuk. 2014, 14, 305–318.
15. T.PemovskaM.KontroB.Yadov. Individualized Systems Medicine Strategy to Tailor Treatments for patients with Chemorefractory Acute Myeloid Leukemia. Cancer Discov. 2013, 3, 1416–1429.